A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
| Autor: | Sun Young Rha, Hyun Cheol Chung, Sang Joon Shin, JaeKyung Roh, Joong Bae Ahn, Hei Cheul Jeung, Sung Hoon Noh |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Time Factors Phases of clinical research Adenocarcinoma Neutropenia Gastroenterology Drug Administration Schedule Stomach Neoplasms Internal medicine Clinical Studies medicine Humans performance status Stomach cancer Survival rate Survival analysis Aged Tegafur Aged 80 and over Performance status business.industry Cancer Combination chemotherapy S-1 Middle Aged Prognosis medicine.disease Survival Analysis Surgery Drug Combinations Oxonic Acid Treatment Outcome Oncology Disease Progression Feasibility Studies Female gastric adenocarcinoma business Follow-Up Studies |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status. In this paper, we describe the first study to evaluate S-1 monotherapy as an option for advanced gastric cancer patients who are not candidates for combination chemotherapy due to poor clinical condition. Fifty-two patients with Eastern Cooperative Oncology Group (ECOG) performance scale 2-3, whose general condition had made use of combination chemotherapy impossible, were enrolled. S-1 was administered to 30 patients as second- or third-line therapy. The initial dose of S-1 was 35 mg m(-2), administered b.i.d for 14 days every 3 weeks. With a median follow-up period of 33 weeks, the median progression-free survival, and overall survival were 11 weeks (95% CI, 8-14) and 33 weeks (95% CI, 19-47), respectively. The overall 1-year survival rate was 29% by intent-to-treat analysis. The overall response rate was 12% (95% CI, 3-21), and the percentage of stable disease was 35%, resulting in the disease control rate of 47% (95% CI, 32-60). Significant drug-related toxicity included grade 3 diarrhoea (14%), anorexia (14%), fatigue (10%), neutropenia (10%), and leucopenia (6%). In conclusion, this study indicated the modest activity of S-1 in gastric cancer patients with poor performance status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|